Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LTC004 + MIL-97 in Advanced Pancreatic Cancer
NCT06255912Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Mar 2024
- Primary completion
- Mar 2029
- Modality
- Cytokines & Interferons
01
Overview
Phase 2, open-label trial of LTC004 in pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Dose Limiting Toxicity at 3 weeks, Maximum Tolerated Dose at 1 year and 1 more. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
LTC004
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06255912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06255912.